He still has to sign Brock Boeser, and when that happens, suddenly the Canucks, who haven been in the playoffs in four years, will find themselves sitting at the salary cap ceiling again.Much of that cap crunch is down to self inflicted bloat, like the US$6 million cap hit he handed to Eriksson in 2016, the four year, US$12 million deal he signed Jay Beagle to last summer, and the five year US$21.875 million extension he signed Brandon Sutter to shortly after trading for the centre in 2015. All contracts that were instantly derided as being big overpayments to players who were unlikely to deliver commensurate value.Chicago Blackhawks goaltender Collin Delia (60) stops a shot by Vancouver Canucks left wing Loui Eriksson (21) during the first period of an NHL hockey game Thursday, Feb. 7, 2019, in Chicago.That said, even with the cap recapture penalty incurred because of Roberto Luongo retirement, Benning was able to sign free agents Tyler Myers, Jordie Benn and Oscar Fantenberg.What he wasn able to do was try to sign a truly handy forward like Gustav Nyquist or Marcus Johansson or a true top pairing defenceman in Jake Gardiner.

Court officials believed at first the sentencing would have to be held in the courthouse holding cell. Dr. Alan J. Actelion said it now expects core earnings to grow in a mid single digit percentage range for 2012, compared with previous guidance for no core earnings growth. That rosier view is the second upward revision to its outlook this year.continues to expect product sales to decrease in the low single digit range for the full year 2012, Chief Financial Officer Andrew Oakley said in a statement.based on an accelerated impact from the cost saving initiative, Actelion has increased its full year earnings outlook for 2012, thereby creating a higher base from which to drive future profitability.Actelion said cost cuts it launched in recent months were already helping profitability with net income for the first half of 174 million Swiss francs ($177 million), compared with a net loss of 262 million in the year ago period.strong half year result for the pharmaceutical company, which initially seems to have passed its health check, analysts at Swiss private bank Notenstein said.The company has been forced to slash costs as pulmonary arterial hypertension (PAH) drug Tracleer, which accounts for 87 percent of the company sales, loses exclusivity in 2015.DRUG DEPENDENCE Actelion announced up to 135 job cuts and other savings measures last week. It said on Thursday that would result in a restructuring charge for the full year, but it has yet to determine the exact amount.Sales of Tracleer fell 4 percent in the first half in local currencies to 752 million francs, due to tough competition in the United States and price cuts in other regions.The firm dependence on Tracleer has been a major concern for shareholders, including Elliott Advisors, the New York hedge fund that built up a chunky stake in Actelion last year and tried but failed to get the group to put itself up for sale.Actelion big new hope is PAH treatment macitentan, which received a boost as a viable top seller earlier this year after it beat expectations in a key clinical trial.It confirmed on Thursday it would submit regulatory filings for macitentan globally by the end of this year.PAH is a disease of the arteries connecting the lungs and the heart.